Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: Programmatic implications for countries phasing out stavudine

• Main Authors: Tang M.W., Rhee S.-Y., Bertagnolio S., Ford N., Holmes S., Sigaloff K.C., Hamers R.L., De Wit T.F.R., Fleury H.J., Kanki P.J., Ruxrungtham K., Hawkins C.A., Wallis C.L., Stevens W., Van Zyl G.U., Manosuthi W., Hosseinipour M.C., Ngo-Giang-Huong N., Belec L., Peeters M., Aghokeng A., Bunupuradah T., Burda S., Cane P., Cappelli G., Charpentier C., Dagnra A.Y., Deshpande A.K., El-Katib Z., Eshleman S.H., Fokam J., Gody J.-C., Katzenstein D., Koyalta D.D., Kumwenda J.J., Lallemant M., Lynen L., Marconi V.C., Margot N.A., Moussa S., Ndung'U T., Nyambi P.N., Orrell C., Schapiro J.M., Schuurman R., Sirivichayakul S., Smith D., Zolfo M., Jordan M.R., Shafer R.W.
• Format: Article
• Language: English
• Published: 2014
• Online Access: http://www.scopus.com/inward/record.url?eid=2-s2.0-84878329003&partnerID=40&md5=7faa842164431e19965a00c998235619; http://cmuir.cmu.ac.th/handle/6653943832/919
• Institution: Chiang Mai University

Background The World Health Organization Antiretroviral Treatment Guidelines recommend phasing-out stavudine because of its risk of long-term toxicity. There are two mutational pathways of stavudine resistance with different implications for zidovudine and tenofovir cross-resistance, the primary can...